Hematologic Oncology

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses an investigational antibody-drug conjugate (ADC) in multiple myeloma.

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses the potential of selinexor in penta-refractory patients with multiple myeloma.

Over the past 2 decades, considerable efforts have focused on the development of therapies that can restore apoptosis in malignant cells.

Aaron R. Hansen, BSc, MBBS, discusses progress with costimulatory immune checkpoints in oncology.

The understanding of the BCL2 oncogene and the BCL-2 protein family have motivated the current advancements in cancer therapeutics that target different members of apoptotic regulatory networks.